Archived Press Releases

• FemmePharma Global Healthcare, Inc. Announces the Divestiture of its Product for the Treatment of Endometriosis to KV Pharmaceutical Company
• FemmePharma, Inc. Creates New Holding Company and Subsidiary
• Femmepharma Named “Company to Watch” by Eastern Technology Council
• Femmepharma CEO to be Honored at 4th Annual Regional Biotech Council Conference
• Femmepharma, Inc. Appoints Ernst & Young as Company’s Independent Auditors
• Gerianne Triangli DiPiano, President & CEO of FemmePharma, Inc., Named Finalist For Ernst & Young Entrepreneur Of The Year® 2004 Award
• Femmepharma, Inc. Presents Phase II Clinical Results of an Investigational Treatment for Endometriosis at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists
• Femmepharma, Inc. Ceo, Gerianne Tringali DiPiano, Recipient of Purple Aster Award from Sons of Italy
• Femmepharma's CEO wins Iris Newman Award at 2004 Ben Franklin Emerging Business Awards
• Femmepharma, Inc. and Emory University team to identify topical microbicides for drug development
• Femmepharma, Inc. announces promising results of phase 2 clinical trial for FP1096, a new investigational treatment for endometriosis
• Femmepharma, Inc. Adds Carolyn D’arville, Ms, Ph.D. And Lisa Rarick, MD, Facog To Scientific Advisory Board
• FemmePharma Invited to Present at Venture Fair for East Coast's Leading Biotechnology Companies
• FemmePharma Receives U.S. Ind Approval for its New Therapeutic Option for Female Urinary Incontinence
• FemmePharma, Inc. Announces New Appointment and Promotions
• FemmePharma, Inc. Secures Round of Financing
• FemmePharma, Inc. Joins Corporate Advisory Board
• Life for Urinary Incontinence Sufferers
• Wayne Pharmaceutical Company Explores New Treatment